Cargando…
Molecular‐targeting therapies against quantitative abnormalities in gene expression with malignant tumors
Genetic mutations in exons of oncogenes and tumor‐suppressor genes causing qualitative abnormalities result in activation of the oncogenes and inactivation of the tumor‐suppressor genes, thereby causing cancer. In contrast, we have previously demonstrated that decreases in the RB promoter activity b...
Autores principales: | Sakai, Toshiyuki, Sowa, Yoshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406604/ https://www.ncbi.nlm.nih.gov/pubmed/28178388 http://dx.doi.org/10.1111/cas.13188 |
Ejemplares similares
-
Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells
por: Ichikawa, Masami, et al.
Publicado: (2015) -
Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
por: Umemura, Shiori, et al.
Publicado: (2020) -
The Flavonoid Apigenin Downregulates CDK1 by Directly Targeting Ribosomal Protein S9
por: Iizumi, Yosuke, et al.
Publicado: (2013) -
Cell Cycle‐dependent Modulation of Promoter Activities of RB and WAF1/Cip1 Genes
por: Matsumoto, Takuji, et al.
Publicado: (1998) -
Smenospongine, a Sesquiterpene Aminoquinone from a Marine Sponge, Induces G1 Arrest or Apoptosis in Different Leukemia Cells
por: Kong, Dexin, et al.
Publicado: (2008)